Sagent Pharmaceuticals, Inc. (SGNT) Misses Q1 EPS by 2c

Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q1 EPS of ($0.30), $0.02 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $38.3 million versus the consensus estimate of $42.31 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
• SentinelOne, Inc. (S) Tops Q2 EPS by 1c; offers guidance
• Workday shares slide 5% as revenue outlook offers little upside surprise